01 8Pradaxa
Main Therapeutic Indication : Hematology
Currency : USD
2020 Revenue in Millions : 1,777
2019 Revenue in Millions : 1,821
Growth (%) : -2
Main Therapeutic Indication : Hematology
Currency : USD
2021 Revenue in Millions : 1,451
2020 Revenue in Millions : 1,777
Growth (%) : -12
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 1,201
2021 Revenue in Millions : 1,451
Growth (%) : -17
Main Therapeutic Indication : Hematology
Currency : USD
2023 Revenue in Millions : 899
2022 Revenue in Millions : 1,201
Growth (%) : -24
Main Therapeutic Indication : Blood Disorders
Currency : USD
2016 Revenue in Millions : 1,468
2015 Revenue in Millions : 1,364
Growth (%) : 8
Main Therapeutic Indication : Blood Disorders
Currency : USD
2018 Revenue in Millions : 1,679
2017 Revenue in Millions : 1,625
Growth (%) : 3%
Main Therapeutic Indication : Hematology
Currency : USD
2019 Revenue in Millions : 1,667
2018 Revenue in Millions : 1,620
Growth (%) : 3
Main Therapeutic Indication : Cardiovascular
Currency : USD
2014 Revenue in Millions : -1%
2013 Revenue in Millions :
Growth (%) :
LOOKING FOR A SUPPLIER?